A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial
暂无分享,去创建一个
Zhenzhen Xu | John D Kalbfleisch | J. Kalbfleisch | R. Silbergleit | M. Haan | W. Meurer | P. Scott | L. Morgenstern | S. Frederiksen | William J Meurer | Lewis B Morgenstern | Robert Silbergleit | Mary N Haan | Phillip A Scott | Shirley M Frederiksen | Zhenzhen Xu
[2] Alan D. Lopez,et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.
[3] Saudi Arabia,et al. in the United States and in , 1981 .
[4] ShyamPrabhakaran,et al. Intravenous Thrombolysis for Stroke Increases Over Time at Primary Stroke Centers , 2012 .
[5] L. Lisabeth,et al. Emergency department evaluation of ischemic stroke and TIA , 2004, Neurology.
[6] Joseph P Broderick,et al. National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate , 2008, Stroke.
[7] Allison M. Kade,et al. Provider perceptions of barriers to the emergency use of tPA for Acute Ischemic Stroke: A qualitative study , 2011, BMC emergency medicine.
[8] B. Ouyang,et al. Intravenous Thrombolysis for Stroke Increases Over Time at Primary Stroke Centers , 2012, Stroke.
[9] A. Rabinstein. Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009 .
[10] Joseph P Broderick,et al. Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.
[11] Geoff Cohen,et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.
[12] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[13] M. Goyal,et al. Treatment of acute ischemic stroke: awareness among general practitioners. , 2010, Neurology India.
[14] M. Hadley,et al. Recommendations for Comprehensive Stroke Centers: A Consensus Statement From the Brain Attack Coalition , 2005, Stroke.
[15] J. Eisenberg,et al. Changing physicians' practices. , 1993, Tobacco control.
[16] Brendan G Carr,et al. ACCESS: acute cerebrovascular care in emergency stroke systems. , 2010, Archives of neurology.
[17] S. Johnston,et al. Why are eligible thrombolysis candidates left untreated? , 2006, American journal of preventive medicine.
[18] Klaus Fassbender,et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial , 2012, The Lancet Neurology.
[19] J. Kalbfleisch,et al. Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams. , 2010, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[20] R. Grubb,et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association , 2003, Stroke.
[21] R. Hornung,et al. US Geographic Distribution of rt-PA Utilization by Hospital for Acute Ischemic Stroke , 2009, Stroke.
[22] Bep Boode,et al. Estimating the Number of Stroke Patients Eligible for Thrombolytic Treatment if Delay Could Be Avoided , 2006, Cerebrovascular Diseases.
[23] Robbert Huijsman,et al. Promoting Thrombolysis in Acute Ischemic Stroke , 2011, Stroke.
[24] Robert Adams,et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. , 2005, Stroke.
[25] A. Demchuk,et al. Improving Delivery of Acute Stroke Therapy: The TLL Temple Foundation Stroke Project , 2002, Stroke.
[26] G. Moneta,et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke , 2009 .
[27] H. Rodgers,et al. Remote specialist assessment for intravenous thrombolysis of acute ischaemic stroke by telephone , 2011, Emergency Medicine Journal.
[28] Dawn Kleindorfer,et al. Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years , 2011, Stroke.
[29] G. D. Graham,et al. Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice: A Meta-Analysis of Safety Data , 2003, Stroke.
[30] P. Scott. Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation. , 2009, Emergency medicine clinics of North America.
[31] Scott Hamilton,et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.
[32] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[33] Werner Hacke,et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.
[34] Areej Al-Wabil,et al. Comparison of active and passive surveillance for cerebrovascular disease: The Brain Attack Surveillance in Corpus Christi (BASIC) Project. , 2002, American journal of epidemiology.
[35] J. Grotta,et al. Sustained benefit of a community and professional intervention to increase acute stroke therapy. , 2003, Archives of internal medicine.
[36] OpeoluAdeoye,et al. Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States , 2011 .
[37] L. Lisabeth,et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. , 2005, Annals of emergency medicine.